Podcast Episodes
Back to Search
The Ron Lanton Report: The Human Bottleneck
In this episode, Ron Lanton argues that healthcare's next constraint isn't capital or technology but rather people.
3 months, 2 weeks ago
Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration
In today's Pharmaceutical Executive Daily, BioMarin and n-Lorem Foundation partner on the first disease-targeted therapy for the recently identified …
3 months, 3 weeks ago
Pharmaceutical Executive Daily: FDA Approves Simtriyo
In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosc…
3 months, 3 weeks ago
Pharmaceutical Executive Daily: FDA Votes to Reduce Restrictions on Four Peptides
In today's Pharmaceutical Executive Daily, an FDA advisory panel narrowly votes to recommend easing restrictions on four unapproved peptides, a suppl…
3 months, 3 weeks ago
Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials
In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial exp…
3 months, 3 weeks ago
Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly
In today's Pharmaceutical Executive Daily, Novo Nordisk sues Eli Lilly over GLP-1 advertising it calls misleading, President Trump announces a phased…
3 months, 3 weeks ago
Pharmaceutical Executive Daily: FDA Grants Emergency Use Authorization to Allplex Assay
In today's Pharmaceutical Executive Daily, FDA grants emergency use authorization for Seegene's multiplex PCR assay, a Pfizer medical lead makes the …
3 months, 4 weeks ago
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of…
3 months, 4 weeks ago
Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta
In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Execut…
4 months ago
Pharmaceutical Executive Daily: FDA Approves Lipfendra
In today's Pharmaceutical Executive Daily, FDA approves Merck's Lipfendra as the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly agrees to…
4 months ago